SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Olofsson Mona)
 

Sökning: WFRF:(Olofsson Mona) > Effects of atenolol...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003467naa a2200457 4500
001oai:DiVA.org:umu-32924
003SwePub
008100331s2010 | |||||||||||000 ||eng|
009oai:gup.ub.gu.se/108915
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-329242 URI
0247 a https://doi.org/10.1177/10760296093495012 DOI
0247 a https://gup.ub.gu.se/publication/1089152 URI
040 a (SwePub)umud (SwePub)gu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Boman, Kurtu Umeå universitet,Medicin4 aut0 (Swepub:umu)kubo0001
2451 0a Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
264 c 2009-10-13
264 1b SAGE Publications,c 2010
338 a print2 rdacarrier
520 a OBJECTIVES: To compare the effects of the beta-blocker atenolol with the angiotensin receptor blocker (ARB) losartan on plasma tissue-type plasminogen activator (tPA) activity and mass concentration, plasminogen activator inhibitor-1 (PAI-1) activity, tPA/PAI-1 complex, and von Willebrand factor (VWF). DESIGN: A prespecified, explorative substudy in 22 patients with hypertension and left ventricular hypertrophy (LVH) performed within randomized multicenter, double-blind prospective study. RESULTS: After a median of 36 weeks of treatment, there were significant differences between the treatment groups, atenolol versus losartan, in plasma median levels of tPA mass (11.9 vs 7.3 ng/mL, P = .019), PAI-1 activity (20.7 vs 4.8 IU/mL, P = .030), and tPA/PAI-1 complex (7.1 vs 2.5 ng/mL, P = .015). In patients treated with atenolol, median levels of tPA mass (8.9-11.9 ng/mL, P = .021) and VWF (113.5%-134.3%, P = .021) increased significantly, indicating a change toward a more prothrombotic state. No significant changes occurred in the losartan group. CONCLUSION: Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group. These findings suggest different fibrinolytic and hemostatic responses to treatment in hypertensive patients with LVH.
653 a fibrinolysis
653 a von Willebrand factor
653 a hypertension
653 a left ventricular hypertrophy
653 a atenolol
653 a losartan
653 a MEDICINE
653 a MEDICIN
7001 a Boman, Jenny Hernestålu Umeå universitet,Medicin4 aut0 (Swepub:umu)jeyhel99
7001 a Andersson, Jonas,d 1977-u Umeå universitet,Medicin4 aut0 (Swepub:umu)jasaon96
7001 a Olofsson, Mona,d 1952-u Umeå universitet,Medicin4 aut0 (Swepub:umu)mool0019
7001 a Dahlöf, Björn,d 1953u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine4 aut0 (Swepub:gu)xdahbj
7102 a Umeå universitetb Medicin4 org
7730 t Clinical and applied thrombosis/hemostasisd : SAGE Publicationsg 16:2, s. 146-152q 16:2<146-152x 1076-0296x 1938-2723
8564 u http://journals.sagepub.com/doi/pdf/10.1177/1076029609349501
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-32924
8564 8u https://doi.org/10.1177/1076029609349501
8564 8u https://gup.ub.gu.se/publication/108915

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy